期刊文献+

广州地区老年科良性前列腺增生的诊断治疗现状 被引量:4

Diagnostic and therapeutic status of the elderly outpatients with benign prostatic hyperplasia in Guangzhoa
原文传递
导出
摘要 目的 了解广州地区老年科门诊伴有下尿路症状的良性前列腺增生(LUTS/BPH)患者的基本情况及诊治状况. 方法 对广州地区三家三级甲等医院的老年科门诊进行调查,对诊断为LUTS/BPH的患者进行生活的基本状况的问卷调查,同时对门诊医师开具的检查和治疗药物进行分析统计. 结果 6140例男性门诊患者中1824例拟诊LUTS/BPH,占29.7%.在有效回收的调查问卷的134例患者中,国际前列腺症状评分(IPSS)轻、中及重度者分别占24.5%、72.5%及3.0%.血清前列腺特异性抗原(PSA)异常率为37.3%.患者最常接受的检查是直肠指检(96.8%)、PSA(88.7%)和经腹B超(84.8%).医师开具的药物最常见为单独使用5-α还原酶抑制剂(44.7%);其次为α-受体拮抗剂及5-α还原酶抑制剂联合使用(24.7%)及其他(植物用药)(16.7%).单独使用α-受体拮抗剂和单独使用植物制剂的比例相近(分别为6.8%和7.1%). 结论 LUTS/BPH是老年科男性患者最常见的疾病之一.医师开具的检查不尽合理,对常规的病史询问、IPSS评分等重视不够,医师开具的治疗药物基本合理. Objective To evaluate the diagnostic and therapeutic status of lower urinary tract symptoms (LUTS) in the elderly outpatients with benign prostatic hyperplasia (BPH) in Guangzhou.Methods The investigation was conducted in outpatient departments for elderly patients in 3 hospitals of Guangzhou. The eligible male patients with LUTS/BPH were chosen from patients who came to the clinic in the process of investigation. Results The 29.7% (1824/6140) of them had history of LUTS/BPH previously or presently. In 134 patients received medical questionnaire, the proportion of LUTS/BPH patients with mild, middle and severe degree based on international prostate symptom score (IPSS) was 24.5%, 72.5% and 3.0% respectively. The abnormal percentage of PSA was 37. 3 %. The most common examinations that patients received were directeral rectun examination (96.8%), PSA (88. 7%) and transabdominal ultrasonography (84.8%). The 44.7% of cases were given the treatment of 5α-reductase inhibitor, and 24.7% of cases received a combination therapy of 5α-reductase inhibitor plus α receptor blocker. The 16.7% of cases were given a combination treatment of 5α-reductase inhibitor plus herbs. The proportion of therapy with α receptor blocker and herbs was similar (6.8% and 7.1% respectively). Conclusions LUTS/BPH is one of the most common diseases in elderly male patients. The examinations conducted by doctors are unreasonable.The doctors are easy to ignore inquirement of patient's history and IPSS. The drugs conducted by doctors are reasonable basically.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2010年第11期949-951,共3页 Chinese Journal of Geriatrics
关键词 前列腺增生 问卷调查 Prostatic hyperplasia Questionnaires
  • 相关文献

参考文献7

  • 1刘明,王建业,于普林,孙振球,吴楠,张传芳,张亚群,王鑫.中国11城市老年科门诊良性前列腺增生现状调查[J].中华老年医学杂志,2009,28(7):597-601. 被引量:7
  • 2Fkagai T~ Maruyama K, Nagata M, et al. Practice patterns regarding prostate cancer and benign prostatic hyperp]asia in Japanese primary care practitioners. Int J Urol,2007,14:412-415.
  • 3Plawker MW, Fleisher JM, Nitti VW, et al. Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer. J Urol, 1996, 155,601-604.
  • 4Fawzy A, Fontenot C, Guthrie R, et al. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Family Med,1997,29:321-325.
  • 5Roehrborn CG, Nucolls JG, Wei JT, et al. The benign prostatic hyperplasia registry and patient survey: study design , methods and patient baseline characteristics. BJU Int,2007,100:813-819.
  • 6Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med,2002,137:917-929.
  • 7Mc Connell JD, Roehrborn CG, Bautista OM, et al. The long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349:2387-2398.

二级参考文献15

  • 1RoehrbornCG,McConnell JD.Benign prostatic hyperplasia etiology,pathophysiology,epidemiology and natural history.In:Wein AJ,Kavoussi LR,Novick AC,et al,eds.Campbell-Walsh Urology,Chapter 86.Philadelphia,USA:Saunders Elsevier,2007.2727-2765.
  • 2Barry SJ.Coffey DS,Walsh PC,et al.The development of human benign prostatic hyperplasia with age.J Urol,1984,132:474-479.
  • 3Girman CJ,Jacobsen SJ,Tsukamoto T,et al.Health-related quality of life associated with lower urinary tract symptoms in four countries.Urology,1998,51:428-436.
  • 4AUA Practice Guidelines Committee.AUA guideline on management of benign prostatic hyperplasia (2003).Chapterl:Diagnosis and treatment recommendations.J Urol,2003,170:530-547.
  • 5Kupelian V,We JT,Leary MPO.Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample.Arch Intern Med,2006,166:2381-2387.
  • 6Roberts RO,Rhodes T,Panser LA,et al.Natural history of prostatism:worry and embarrassment from urinary symptoms and health care-seeking behavior.Urol,1994,43:621-628.
  • 7Roehrborn CG,Nuckolls JG,Wei JT,et al.The benign prostatic hyperplasia registry and patient survey:study design,methods and patient baseline characteristics.BJU Int,2007,100:813-819.
  • 8Robertson C,Link CL,Onel E.The impact of lower urinary tract symptoms and eomorbidities on quality of life:the BACH and UREPIK studies.BJU Int,2007,99:347-354.
  • 9Andersson SO,Rashidkhani B,Karlberg L,et al.Prevalence of lower urinary tract symptoms in men aged 45-79 years:a population-based study of 40 000 Swedish men.BJU Int,2004,94:327-331.
  • 10Irani J,Brown CT,Meulen J,et al.A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms:are all guidelines the same? BJU Int,2003,92:937-942.

共引文献6

同被引文献14

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部